The CDC asked for emergency use of the PCR test.
CDC shared: ‘’In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider the adoption of a multiplexed method that can facilitate the detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.’’
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
They tell the doctors to use the tests that can tell the difference. People have to know this.
The CDC asked for emergency use in July, after December 31.
People commented on Twitter about this:
On Dec 31, 2021, the CDC will withdraw the use of the PCR test for covid testing. They’ve finally admitted the test doesn’t differentiate between the flu & the Corona! Hmm that’s why the flu has been eradicated for the last 2 yrs? Sorry CDC we were aware & so were you! Liars!
— Domenica D'Elia (@domenicadelia22) December 29, 2021
CDC withdraw use apparently *not* down to fact that it CANNOT distinguish between flu & C19, but as there's no longer much call for the tests – Mmm but US topped best part of half a mill + tests in one day?
MMS are inventing a handy explanation it seems … Open your eyes FGS!!? pic.twitter.com/vB0lw6yoDd
— Zor (@Zorozum) December 30, 2021
December 31, 2021 – CDC to WITHDRAW Emergency Use Authorization for PCR Tests Used to Detect – Epidemic was Total FRAUD https://t.co/UJJoXj5Rb1
— Lauretta (@Tanfox13) January 1, 2022
Everything is for money; they make the world goes round.
Roche has earned Food and Drug Administration emergency use authorization for the cobas SARS-CoV-2 nucleic acid test for use on the cobas Liat system. According to Roche, this singleplex test is the first real-time reverse transcriptase-polymerase chain reaction test that identifies SARS-CoV-2 infection within 20 minutes, and that is authorized to screen both symptomatic and asymptomatic persons at the point of care. It also offers broad SARS-CoV-2 strain coverage as monitored by Roche’s ongoing variant surveillance program. The cobas Liat system fully automates the testing process and features a simplified workflow that enables healthcare professionals to perform this test with minimal training. The cobas SARS-CoV-2 nucleic acid test is intended for use at a wide range of point-of-care settings, including emergency and primary care settings, physician offices, and other SARS-CoV-2 screening locations. It is also available in markets accepting the CE mark.
This test is going to be as efficient as the last.